Genmab | GEN - Current Assets


Genmab reported DKK2.8B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Almirall EUR 747.1M 33.12M Jun/2026
Amarin USD 612.88M 10.12M Sep/2026
Amgen USD 34.36B 598M Sep/2026
argenx SE USD 8.07B 1.17B Jun/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Bayer EUR 39.6B 5.96B Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Demant DKK 10.2B 130M Jun/2026
Exelixis USD 1.32B 70.8M Sep/2026
Fresenius Medical Care EUR 7.84B 150.6M Sep/2026
Genmab DKK 2.8B 228M Jun/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
GN Store Nord DKK 20.15B 14.52B Sep/2026
GRIFOLS EUR 5.35B 40M Sep/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Insmed USD 1.71B 72.59M Sep/2026
Lakefront Biotherapeutics EUR 2.31B 751.38M Jun/2026
Lonza CHF 8B 3.41B Dec/2025
Merck EUR 13.77B 393M Jun/2026
Novartis USD 28.75B 1.4B Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 33.21B 1.68B Sep/2026
UCB EUR 6.05B 733M Dec/2025